India’s wait for the covid-19 vaccine is over. The Drug Controller General of India (DCGI) on Sunday approved the limited emergency use of two vaccines in the country.
Source- Naidunia
‘Kovishield’ which is Oxford’s covid-19 vaccine and ‘Covaxin’ which is indigenously developed by Bharat Biotech, has cleared the way for a comprehensive vaccination campaign, said DCGI in the press conference on Sunday. Drug Controller General of India V.G. Somani said that trial runs submitted by both the companies have been approved for “limited use”. These vaccines will be stored at temperatures ranging from 2 to 8 degrees.
Two doses will be given for both the vaccines.
Serum Institute of India which is the world’s largest vaccine manufacturer has partnered with AstraZeneca to produce ‘Kovishield’.
Bharat Biotech developed the ‘COVAXIN’ in alliance with the Indian Council of Medical Research (ICMR). It has been given the approval to be used in ‘clinical trial mode’ with great caution in emergencies. This means that while applying this vaccine, all the protocols will have to be followed very strictly. In Covaxine vaccination, the ‘scale of giving the vaccine and not giving’ is fixed. For example, if a person has already suffered from corona, they cannot be given this vaccine.
India’s vaccination process is expected to start on 14th January.
0 Comments